



## Ocular Drug Delivery – State-of-the-Art and New Concepts

20 - 21 June 2016, Berlin, Germany  
Course no. 6639

The APV high-toned conferences are dedicated to challenging pharmaceutical topics which will be discussed in a thorough and comprehensive way from different scientific and regulatory perspectives by international best-known specialists in their area of daily work or research. These conferences are unique meeting places for networking and top-class education in one go.

## SCOPE / OUTLINE:

There is an increasing interest in developing novel and improved medicines for the treatment of ocular diseases such as age related macular degeneration (AMD), diabetic retinopathies, glaucoma, dry eye.

To enable development of new medicines not only a better understanding of the underlying disease mechanisms and the relevant targets is required, but also an in depths understanding of the drug distribution and transport mechanisms in the eye. Novel drug delivery systems and formulation design principles play a crucial role in delivering drug molecules to targets in the front and in particular in the back of the eye. Other key aspects include the route and frequency of drug administration including controlled and extended drug release and improved patient compliance.

World leading experts from Europe and America working in preclinical and clinical R&D areas in academia, industry and CROs will provide insights to formulation related development aspects and discuss adequate approaches such as:

- Basic aspects of ocular diseases and treatment options by using modern drug delivery systems ranging from eye drops to controlled release systems
- Drug transport and pharmacokinetics in the eye
- Overview on available and novel formulations principles and drug delivery systems
- Challenges and hurdles in the development of novel drug delivery concepts including packaging
- Options for preclinical and clinical testing ocular delivery systems (CRO's)
- Case studies

## TARGET GROUP:

- Scientists, technical experts, project and line managers from various areas of ocular drug product development involved into research and development of ophthalmic drug products for new drug candidates (small and large molecules)

## CONFERENCE MODERATORS:



- Professor emeritus Dr. Robert Gurny, University of Geneva, former President of the School of Pharmaceutical Sciences at the University of Geneva, Switzerland is a world leading expert in the area of ophthalmic formulations and drug delivery. His is active in the field of ocular drug delivery since more than thirty years and has co-authored over 150 papers in the field.



- Dr. Rainer Alex, has more than 25 years of experience in the area of drug product development and drug delivery research. He is currently involved into early evaluation and development activities for ophthalmic drug products in the Preclinical and Early Development unit at the Roche Innovation Center Basel at F. Hoffmann – La Roche AG in Basel.

# PROGRAMME

**Monday, 20 June 2016, 13:00-17:30**

## **Welcome and Introduction, Scope of Conference**

Dr. Rainer Alex  
F. Hoffmann-La Roche AG, Basel, Switzerland  
Prof. Robert Gurny  
University of Geneva – University of Lausanne,  
Geneva, Switzerland

## **Overview on ocular diseases – Current treatment (Medical view)**

Prof. Francine Behar-Cohen, Medical Director  
Hôpital Ophthalmique Jules-Gonin/UNIL University  
of Lausanne, Switzerland

## **Ocular anatomy, physiology, pharmacokinetics and pK modeling**

Prof. Arto Urtti, Director, Centre for Drug Research  
University of Helsinki, Helsinki, Finland

## **Overview on available dosage forms and delivery options – from eye drops to drug delivery systems**

- marketed products
- technological view

Dr. Pascal Furrer, Senior Lecturer  
University of Geneva, Geneva, Switzerland

## **Novel drug delivery systems for ocular diseases – opportunities and challenges**

Prof. Francine Behar-Cohen, Medical Director  
Hôpital Ophthalmique Jules-Gonin/UNIL University  
of Lausanne, Switzerland

## **Basic aspects of formulation development and regulatory (pharmacopeia) requirements for ophthalmic products**

Dr. Pascal Furrer, Senior Lecturer  
University of Geneva, Geneva, Switzerland

## **Drug delivery to the back of the eye**

Dr. Ann Daugherty, Senior Manager, Drug Delivery  
Genentech Inc., San Francisco, United States

## **Wrap up / discussion**

## **City tour and Networking dinner**

**Tuesday, 21 June 2016, 08:45-16:15**

## **Welcome Day 2**

Dr. Rainer Alex  
Prof. Robert Gurny

## **Nanosystems**

Dr. Doris Gabriel, Senior Scientist  
Apidel, Geneva, Switzerland

## **Gene Delivery to the eye**

Dr. Jean-Philippe Combal, Chief Operating Officer  
GenSight, Paris, France

## **Sterile suspensions formulations**

Excelvision/Fareva

## **Novel device approaches for ocular delivery**

Dr. Signe Erickson, Senior Vice President, Product  
Development  
ForSight Vision4, San Francisco, United States

## **Pre-clinical in vivo (animal) testing of ocular formulations and drug delivery systems (FOTE; eye drops, subconjunctival)**

Dr. Laurence Feraille, Preclinical Models Development  
IRIS Pharma, La Gaude, France

## **Pre-clinical in vivo (animal) testing of ocular formulations and drug delivery (BOTE)-implants, ivt injections**

Dr. Margaret E. Collins, Associate Director, Research  
Program Director, Ocular Toxicology Preclinical Services  
Charles River Labs, Reno, United States

## **Blow-Fill-Seal technology for single and multiple dose eye drop formulations**

Dr. Otto Ernst Schubert, General Manager, Director  
Maropack, Zell, Switzerland

## **New multidose dispenser for eye drops**

Loïc Marchin, Founder, CEO  
Pylote, Drémil-Lafage, France

## **Case study I: Cationic emulsions in ophthalmology: from bench to bedside**

Frédéric Lallemand, Responsible research  
and innovation  
Santen S.A.S., Evry Cedex, France

## **Case study II: From concept to phase 3 in eye gene therapies: Key requirements and potential strategic impact over the development phases**

Dr. Jean-Philippe Combal, Chief Operating Officer  
GenSight, Paris, France

## **Final discussion / Q&A**

## Location

WYNDHAM GARDEN  
Berlin Mitte  
Osloer Str. 1  
13359 Berlin  
Germany  
T: +49 30 495 000-0  
F: +49 30 495 000-495  
E: info@wyndamgardenberlin.com

I herewith repealable authorise APV to use my E-mail address to send me APV relevant material including current programme information. My acceptance can be cancelled at any time in writing

## Date

Course no. 6639  
from 20 June 2016 13:00 h  
to 21 June 2016 16:45 h

## Registration fee

APV member 1460 EUR  
Non-member 1590 EUR  
(free of VAT according to § 4,22 UStG)

Coffee breaks, dinner on the first day, city tour, lunch on the second day and electronic proceedings included.

## Registration

APV-Geschäftsstelle  
Kurfürstenstraße 59  
55118 Mainz/Germany  
Phone: +49 6131 9769-0  
Fax: +49 6131 9769-69  
e-mail: apv@apv-mainz.de

You will receive a confirmation of your registration with the invoice.

Members of authorities pay half of the APV member's and non-member's registration fee respectively.

## Hotel reservation

WYNDHAM GARDEN  
Berlin Mitte  
Osloer Str. 1  
13359 Berlin  
Germany  
T: +49 30 495 000-3223  
F: +49 30 495 000-495  
E: info@wyndamgardenberlin.com

Participants should make their own hotel reservation referring to the APV seminar.

Deadline for special conference rate: 25 May 2016.

Special rate:  
Single room incl. breakfast buffet from 89 EUR per night.

Mainz, March 2016

## Ocular Drug Delivery CN 6639

### Registration

As soon as you have found a seminar of your interest, it is very easy to register for it via fax, e-mail or online. We will process your registration promptly and certainly are available for any questions that may arise.

### Registration confirmation

After your registration was successfully processed, you will receive a confirmation.

### Before the event

A few days before the event starts, you will receive important information about the seminar, such as time, date, addresses etc.

### After the event

You will receive a certificate confirming your participation. Furthermore, we would like to ask you to fill-in our evaluation sheet to make sure we get better every time.

### Follow-up

After the event, we are open to receive any suggestions and critique that might arise during the seminar and will certainly help you with further questions you may have.

- pay via invoice  
 pay via credit card (fill in below)  
 AMEX  
 Visa  
 Mastercard

Card Holder

Card No.

Valid until

CVC Code

Title, First Name, Last Name \*

Company Name \*

Company Address \*

Location \*

Zip-Code \*

Phone \*

Department \*

E-mail Address Participant\*

Order No. or Billing Address

APV Member

Non-Member

Date

Signature

\*Mandatory

Arbeitsgemeinschaft für Pharmazeutische  
Verfahrenstechnik e.V.  
Gemeinnütziger wissenschaftlicher Verein  
International Association for Pharmaceutical  
Technology

APV-Geschäftsstelle  
Kurfürstenstraße 59  
55118 Mainz/Germany  
Phone: +49 6131 9769-0  
Fax: +49 6131 9769-69  
e-mail: apv@apv-mainz.de

[www.apv-mainz.de](http://www.apv-mainz.de)